Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma

Morie Gertz, Martha Lacy, D. J. Inwards, D. A. Gastineau, Ayalew Tefferi, M. G. Chen, Thomas Elmer Witzig, P. R. Greipp, Mark R Litzow

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The optimal timing of stem cell transplantation for multiple myeloma is controversial. Late stem cell collection is undesirable because of the inability to mobilize stem cells. We report on 64 recipients of stem cells collected within 1 year after diagnosis, none of whom had transplantation in plateau phase of their disease. Patients seen within 12 months after diagnosis received four cycles of standard vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy and then had stem cells mobilized. Patients were then placed on maintenance vincristine, BCNU, melphalan, cyclophosphamide, and prednisone or melphalan and prednisone chemotherapy for 12 cycles. At the sign of first progression, transplantation occurred. Fourteen patients were refractory to VAD chemotherapy, 20 relapsed on maintenance chemotherapy, and 30 relapsed off chemotherapy. The time to platelet engraftment was not affected by the duration of stem cell cryopreservation or extent of chemotherapy exposure after mobilization. The complete response rate was 34%. The actuarial median survival from initial diagnosis, from transplant day 0, and post-transplant progression-free survival was 51, 20 and 11.4 months, respectively. The patient status at transplantation and percentage of plasma cells circulating in the blood at apheresis influenced post-transplant survival; circulating plasma cells, status at transplantation and plasma cell labeling index influenced progression-free survival. Response duration was shorter in patients relapsing on chemotherapy.

Original languageEnglish (US)
Pages (from-to)45-50
Number of pages6
JournalBone Marrow Transplantation
Volume26
Issue number1
StatePublished - 2000

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Stem Cells
Drug Therapy
Vincristine
Plasma Cells
Transplantation
Melphalan
Prednisone
Transplants
Doxorubicin
Dexamethasone
Disease-Free Survival
Maintenance Chemotherapy
Carmustine
Blood Component Removal
Cryopreservation
Cyclophosphamide
Blood Platelets
Maintenance

Keywords

  • High-dose chemotherapy
  • Labeling index
  • Multiple myeloma
  • Refractory myeloma
  • Stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. / Gertz, Morie; Lacy, Martha; Inwards, D. J.; Gastineau, D. A.; Tefferi, Ayalew; Chen, M. G.; Witzig, Thomas Elmer; Greipp, P. R.; Litzow, Mark R.

In: Bone Marrow Transplantation, Vol. 26, No. 1, 2000, p. 45-50.

Research output: Contribution to journalArticle

@article{611ec479f06c4de5b88dc09f989ae2d9,
title = "Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma",
abstract = "The optimal timing of stem cell transplantation for multiple myeloma is controversial. Late stem cell collection is undesirable because of the inability to mobilize stem cells. We report on 64 recipients of stem cells collected within 1 year after diagnosis, none of whom had transplantation in plateau phase of their disease. Patients seen within 12 months after diagnosis received four cycles of standard vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy and then had stem cells mobilized. Patients were then placed on maintenance vincristine, BCNU, melphalan, cyclophosphamide, and prednisone or melphalan and prednisone chemotherapy for 12 cycles. At the sign of first progression, transplantation occurred. Fourteen patients were refractory to VAD chemotherapy, 20 relapsed on maintenance chemotherapy, and 30 relapsed off chemotherapy. The time to platelet engraftment was not affected by the duration of stem cell cryopreservation or extent of chemotherapy exposure after mobilization. The complete response rate was 34{\%}. The actuarial median survival from initial diagnosis, from transplant day 0, and post-transplant progression-free survival was 51, 20 and 11.4 months, respectively. The patient status at transplantation and percentage of plasma cells circulating in the blood at apheresis influenced post-transplant survival; circulating plasma cells, status at transplantation and plasma cell labeling index influenced progression-free survival. Response duration was shorter in patients relapsing on chemotherapy.",
keywords = "High-dose chemotherapy, Labeling index, Multiple myeloma, Refractory myeloma, Stem cell transplant",
author = "Morie Gertz and Martha Lacy and Inwards, {D. J.} and Gastineau, {D. A.} and Ayalew Tefferi and Chen, {M. G.} and Witzig, {Thomas Elmer} and Greipp, {P. R.} and Litzow, {Mark R}",
year = "2000",
language = "English (US)",
volume = "26",
pages = "45--50",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma

AU - Gertz, Morie

AU - Lacy, Martha

AU - Inwards, D. J.

AU - Gastineau, D. A.

AU - Tefferi, Ayalew

AU - Chen, M. G.

AU - Witzig, Thomas Elmer

AU - Greipp, P. R.

AU - Litzow, Mark R

PY - 2000

Y1 - 2000

N2 - The optimal timing of stem cell transplantation for multiple myeloma is controversial. Late stem cell collection is undesirable because of the inability to mobilize stem cells. We report on 64 recipients of stem cells collected within 1 year after diagnosis, none of whom had transplantation in plateau phase of their disease. Patients seen within 12 months after diagnosis received four cycles of standard vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy and then had stem cells mobilized. Patients were then placed on maintenance vincristine, BCNU, melphalan, cyclophosphamide, and prednisone or melphalan and prednisone chemotherapy for 12 cycles. At the sign of first progression, transplantation occurred. Fourteen patients were refractory to VAD chemotherapy, 20 relapsed on maintenance chemotherapy, and 30 relapsed off chemotherapy. The time to platelet engraftment was not affected by the duration of stem cell cryopreservation or extent of chemotherapy exposure after mobilization. The complete response rate was 34%. The actuarial median survival from initial diagnosis, from transplant day 0, and post-transplant progression-free survival was 51, 20 and 11.4 months, respectively. The patient status at transplantation and percentage of plasma cells circulating in the blood at apheresis influenced post-transplant survival; circulating plasma cells, status at transplantation and plasma cell labeling index influenced progression-free survival. Response duration was shorter in patients relapsing on chemotherapy.

AB - The optimal timing of stem cell transplantation for multiple myeloma is controversial. Late stem cell collection is undesirable because of the inability to mobilize stem cells. We report on 64 recipients of stem cells collected within 1 year after diagnosis, none of whom had transplantation in plateau phase of their disease. Patients seen within 12 months after diagnosis received four cycles of standard vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy and then had stem cells mobilized. Patients were then placed on maintenance vincristine, BCNU, melphalan, cyclophosphamide, and prednisone or melphalan and prednisone chemotherapy for 12 cycles. At the sign of first progression, transplantation occurred. Fourteen patients were refractory to VAD chemotherapy, 20 relapsed on maintenance chemotherapy, and 30 relapsed off chemotherapy. The time to platelet engraftment was not affected by the duration of stem cell cryopreservation or extent of chemotherapy exposure after mobilization. The complete response rate was 34%. The actuarial median survival from initial diagnosis, from transplant day 0, and post-transplant progression-free survival was 51, 20 and 11.4 months, respectively. The patient status at transplantation and percentage of plasma cells circulating in the blood at apheresis influenced post-transplant survival; circulating plasma cells, status at transplantation and plasma cell labeling index influenced progression-free survival. Response duration was shorter in patients relapsing on chemotherapy.

KW - High-dose chemotherapy

KW - Labeling index

KW - Multiple myeloma

KW - Refractory myeloma

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=0033938845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033938845&partnerID=8YFLogxK

M3 - Article

C2 - 10918404

AN - SCOPUS:0033938845

VL - 26

SP - 45

EP - 50

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -